AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29996792 — intervention group
Group type: EXPERIMENTAL
Intervention: Young Women's Health CoOp (YWHC) intervention
Number of subjects: 0
Study 29996792 — intervention group
Group type: COMPARATOR
Intervention: Standard HCT (control)
Number of subjects: 0
Study 26906148 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training (ET) on a cycle ergometer, performed daily at 50%-60% of maximal exercise capacity for 12 months.
Number of subjects: 37
Study 25022743 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted blanket
Number of subjects: 73
Study 25022743 — intervention group
Group type: COMPARATOR
Intervention: Control blanket (usual weight blanket)
Number of subjects: 73
Study 22327039 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral CR oxycodone 10 mg/q12h plus IV paracetamol 1g/q6h
Number of subjects: 260
Study 22327039 — intervention group
Group type: COMPARATOR
Intervention: Epidural anesthesia with continuous infusion of levobupivacaine 0.125% and sufentanil 0.7 mcg/mL at 7 mL/h
Number of subjects: 260
Study 20231783 — intervention group
Group type: EXPERIMENTAL
Intervention: DMST (dynamic muscular stabilization techniques)
Number of subjects: 141
Study 20231783 — intervention group
Group type: COMPARATOR
Intervention: CONV (conventional treatment)
Number of subjects: 141
Study 18042917 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK infusion therapy
Number of subjects: 2748
Study 16518521 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionylcarnitine (PLC) 600 mg as a single bolus followed by 1 mg/kg/min for 60 minutes
Number of subjects: 36
Study 16518521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 16518521 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionylcarnitine (PLC)
Number of subjects: 36
Study 14557150 — intervention group
Group type: EXPERIMENTAL
Intervention: CRA + vouchers
Number of subjects: 100
Study 14557150 — intervention group
Group type: COMPARATOR
Intervention: Vouchers only
Number of subjects: 100
Study 10617697 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal fever >100.4 degrees F
Number of subjects: 1218
Study 10617697 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal fever >101 degrees F
Number of subjects: 1218
Study 10617697 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal fever
Number of subjects: 1218
Study 10617697 — intervention group
Group type: COMPARATOR
Intervention: Afebrile women
Number of subjects: 1218
Study 9104600 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (1.5 micrograms/kg)
Number of subjects: 13
Study 9104600 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (1.3 micrograms/kg)
Number of subjects: 13
Study 9104600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 8265735 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH
Number of subjects: 10
Study 2863674 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloramphenicol alone by intramuscular injection
Number of subjects: 367
Study 2863674 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol plus penicillin by intravenous injection
Number of subjects: 367
Study 31504417 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab (50 mg)
Number of subjects: 4848
Study 31504417 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab (150 mg)
Number of subjects: 4848
Study 31504417 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab (300 mg)
Number of subjects: 4848
Study 31504417 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab (any dose)
Number of subjects: 4848
Study 31504417 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-18 (measured 3 months after canakinumab initiation)
Number of subjects: 4848
Study 31504417 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 (measured 3 months after canakinumab initiation)
Number of subjects: 4848
Study 31504417 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-18 and IL-6 (baseline and on-treatment analyses)
Number of subjects: 4848
Study 31504417 — intervention group
Group type: COMPARATOR
Intervention: Canakinumab
Number of subjects: 4848
Study 29723901 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide and Diphenhydramine (MAD)
Number of subjects: 70
Study 29723901 — intervention group
Group type: COMPARATOR
Intervention: Codeine
Number of subjects: 70
Study 27810185 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective CPAP for six weeks
Number of subjects: 36
Study 27810185 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP for six weeks
Number of subjects: 36
Study 24284234 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 614
Study 24284234 — intervention group
Group type: COMPARATOR
Intervention: Perphenazine
Number of subjects: 614
Study 24284234 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine
Number of subjects: 614
Study 24284234 — intervention group
Group type: COMPARATOR
Intervention: Ziprasidone
Number of subjects: 614
Study 24284234 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 614
Study 22631861 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive recruitment tactics including hiring a recruitment director, expanding sites, and broadening eligibility criteria.
Number of subjects: 2502
Study 22631861 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment tactics implemented from 2004 to 2008.
Number of subjects: 2502
Study 22631861 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment tactics implemented in 2006, 2007, and 2008.
Number of subjects: 2502
Study 20171327 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 65
Study 20171327 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied relaxation (AR)
Number of subjects: 65
Study 20171327 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WL)
Number of subjects: 65
Study 19066278 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline regimens
Number of subjects: 54189
Study 19066278 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-drug taxane
Number of subjects: 54189
Study 19066278 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of anthracyclines with taxane
Number of subjects: 54189
Study 19066278 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxane-based combination with capecitabine or gemcitabine
Number of subjects: 54189
Study 19066278 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular targeted treatments
Number of subjects: 54189
Study 16188185 — intervention group
Group type: EXPERIMENTAL
Intervention: Running horizontal mattress suture
Number of subjects: 55
Study 16188185 — intervention group
Group type: COMPARATOR
Intervention: Simple running suture
Number of subjects: 55
Study 12592331 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone (HDMP) 900-600 mg/m(2) orally
Number of subjects: 205
Study 12592331 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose prednisolone 60 mg/m(2)/day orally
Number of subjects: 205
Study 12592331 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone (HDMP) in high-risk subgroup
Number of subjects: 205
Study 12592331 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone (HDMP) in high-risk subgroup aged </=2 or >/=10 years
Number of subjects: 205
Study 12592331 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone (HDMP) in high-risk subgroup with WBC count >/=50 x 10(9)/l
Number of subjects: 205
Study 12592331 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone (HDMP)
Number of subjects: 205
Study 10229456 — intervention group
Group type: EXPERIMENTAL
Intervention: Group communication treatment (5 hours weekly for 4 months)
Number of subjects: 24
Study 10229456 — intervention group
Group type: COMPARATOR
Intervention: Deferred treatment (support, performance, or movement groups)
Number of subjects: 24
Study 8949808 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural anaesthesia in group I (no previous procedures)
Number of subjects: 491
Study 8949808 — intervention group
Group type: COMPARATOR
Intervention: Extradural anaesthesia in group II (one previous procedure)
Number of subjects: 491
Study 8949808 — intervention group
Group type: COMPARATOR
Intervention: Extradural anaesthesia in group III (two or more previous procedures)
Number of subjects: 491
Study 8949808 — intervention group
Group type: COMPARATOR
Intervention: Flexible extraduroscopy in 32 patients
Number of subjects: 491
Study 1806520 — intervention group
Group type: EXPERIMENTAL
Intervention: Transparent hydrocolloid dressing (THCD)
Number of subjects: 12
Study 1806520 — intervention group
Group type: COMPARATOR
Intervention: Traditional paraffin gauze dressing (PGD)
Number of subjects: 12
Study 6616993 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 14
Study 6616993 — intervention group
Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 14
Study 31556095 — intervention group
Group type: EXPERIMENTAL
Intervention: milrinone (0.4 and 0.8 µg/kg/min, n = 16)
Number of subjects: 31
Study 31556095 — intervention group
Group type: EXPERIMENTAL
Intervention: levosimendan (0.1 and 0.2 µg/kg/min, n = 15)
Number of subjects: 31
Study 30145660 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronectomy with adjunctive guided bone regeneration (GBR)
Number of subjects: 48
Study 30145660 — intervention group
Group type: COMPARATOR
Intervention: Coronectomy alone (control group)
Number of subjects: 48
Study 30145660 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study 28207503 — intervention group
Group type: EXPERIMENTAL
Intervention: Clamping drainage for the first 4 postoperative hours
Number of subjects: 121
Study 28207503 — intervention group
Group type: COMPARATOR
Intervention: Nonclamping drainage
Number of subjects: 121
Study 24980988 — intervention group
Group type: COMPARATOR
Intervention: Etanercept 50 mg BIW
Number of subjects: 282
Study 24980988 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg QW plus topical agent as needed
Number of subjects: 282
Study 24980988 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Etanercept 50 mg BIW and Etanercept 50 mg QW plus topical agent)
Number of subjects: 282
Study 23542053 — intervention group
Group type: EXPERIMENTAL
Intervention: Online game suite designed to train multiple cognitive abilities
Number of subjects: 60
Study 23542053 — intervention group
Group type: COMPARATOR
Intervention: Control arm with online activities that simulated the games but with low level interactivity and no calibration of difficulty
Number of subjects: 60
Study 21871624 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg once daily
Number of subjects: 1255
Study 21871624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1255
Study 17618526 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with avoidant personality disorder (APD)
Number of subjects: 335
Study 17618526 — intervention group
Group type: COMPARATOR
Intervention: Patients without avoidant personality disorder (APD)
Number of subjects: 335
Study 17618526 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of APD
Number of subjects: 335
Study 16484170 — intervention group
Group type: EXPERIMENTAL
Intervention: Group supervision
Number of subjects: 23
Study 16484170 — intervention group
Group type: COMPARATOR
Intervention: Individual supervision
Number of subjects: 23
Study 15097153 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) 0.1 mg/kg daily (DD)
Number of subjects: 757
Study 15097153 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) 0.1 mg/kg alternate days (AD)
Number of subjects: 757
Study 15097153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 757
Study 10696916 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (IFNbeta-1a) treatment for 6 months
Number of subjects: 0
Study 9350882 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose oral vitamin A supplementation
Number of subjects: 592
Study 9350882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 592
Study 8223076 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactogest (4 capsules, approx 6000 IU)
Number of subjects: 0
Study 8223076 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactaid (2 caplets, approx 6000 IU)
Number of subjects: 0
Study 8223076 — intervention group
Group type: EXPERIMENTAL
Intervention: DairyEase (2 tablets, approx 6000 IU)
Number of subjects: 0
Study 8223076 — intervention group
Group type: COMPARATOR
Intervention: Lactogest (2 capsules, approx 3000 IU)
Number of subjects: 0
Study 8223076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8223076 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme treatment (3000 or 6000 IU) with 50 g of lactose
Number of subjects: 0
Study 2433872 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% methotrexate cream
Number of subjects: 5
Study 2433872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 30871349 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP levels in patients with AF
Number of subjects: 3835
Study 30871349 — intervention group
Group type: COMPARATOR
Intervention: NT-proBNP levels in patients without AF
Number of subjects: 3835
Study 30871349 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary composite outcome of cardiovascular death or HF hospitalization in patients with AF
Number of subjects: 3835
Study 30871349 — intervention group
Group type: COMPARATOR
Intervention: Primary composite outcome of cardiovascular death or HF hospitalization in patients without AF
Number of subjects: 3835
Study 30871349 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted analyses of NT-proBNP levels
Number of subjects: 3835
Study 30871349 — intervention group
Group type: COMPARATOR
Intervention: NT-proBNP <400 pg/mL
Number of subjects: 3835
Study 30871349 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP ≥400 pg/mL
Number of subjects: 3835
Study 30251591 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ESS (1-hour daily during hospitalization)
Number of subjects: 102
Study 30251591 — intervention group
Group type: COMPARATOR
Intervention: Low-dose ESS (placebo)
Number of subjects: 102
Study 29064791 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin at a dose of 120 mg per os daily added to standard treatment
Number of subjects: 85
Study 29064791 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment without quercetin
Number of subjects: 85
Study 25603743 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates breathing technique (POW) during trunk flexion
Number of subjects: 19
Study 25603743 — intervention group
Group type: COMPARATOR
Intervention: Trunk flexion without the Pilates breathing technique (NORM)
Number of subjects: 19
Study 22093961 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 320
Study 22093961 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 320
Study 22093961 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES) and Bare-metal stent (BMS)
Number of subjects: 320
Study 22093961 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who did not experience TLR within 1-year
Number of subjects: 320
Study 22093961 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who experienced TLR within 1-year
Number of subjects: 320
Study 22093961 — intervention group
Group type: EXPERIMENTAL
Intervention: TLR within 1 year
Number of subjects: 320
Study 22093961 — intervention group
Group type: EXPERIMENTAL
Intervention: Small vessels treatment
Number of subjects: 320
Study 22015082 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinated discharge care organized by a discharge coordinator
Number of subjects: 0
Study 22015082 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 18427699 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific Resistance Training (SRT)
Number of subjects: 549
Study 18427699 — intervention group
Group type: EXPERIMENTAL
Intervention: All-round Physical Exercise (APE)
Number of subjects: 549
Study 18427699 — intervention group
Group type: COMPARATOR
Intervention: Reference group (general health-promoting activities)
Number of subjects: 549
Study 16949939 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical high-velocity low-amplitude (HVLA) manipulation
Number of subjects: 70
Study 16949939 — intervention group
Group type: COMPARATOR
Intervention: Control mobilization procedure
Number of subjects: 70
Study 12734892 — intervention group
Group type: EXPERIMENTAL
Intervention: Various interventions in randomized controlled trials (RCT) on systemic lupus erythematosus (SLE)
Number of subjects: 2257
Study 12734892 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephritis trials
Number of subjects: 2257
Study 12734892 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials that specified withdrawals per arm
Number of subjects: 2257
Study 12734892 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials that used intention-to-treat analyses
Number of subjects: 2257
Study 12734892 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials published in 1999-2002
Number of subjects: 2257
Study 12734892 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger trials
Number of subjects: 2257
Study 12734892 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials that described reasons for withdrawals
Number of subjects: 2257
Study 11601562 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet Group (individual dietary counseling to increase intake of iron-rich foods)
Number of subjects: 75
Study 11601562 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplement Group (50 mg iron/day as amino acid chelate)
Number of subjects: 75
Study 11601562 — intervention group
Group type: COMPARATOR
Intervention: Placebo Group
Number of subjects: 75
Study 9715679 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide 2.0% three times daily
Number of subjects: 298
Study 9715679 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.5% twice daily
Number of subjects: 298
Study 9715679 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 0.5% twice daily
Number of subjects: 298
Study 7527106 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril 4 mg o.d.
Number of subjects: 180
Study 7527106 — intervention group
Group type: COMPARATOR
Intervention: Captopril 50 mg b.i.d.
Number of subjects: 180
Study 7527106 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril + HCTZ 25 mg (if needed)
Number of subjects: 180
Study 7527106 — intervention group
Group type: COMPARATOR
Intervention: Captopril + HCTZ 25 mg (if needed)
Number of subjects: 180
Study 2525984 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac 200 mg three times a day
Number of subjects: 0
Study 2525984 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac 300 mg twice a day
Number of subjects: 0
Study 2525984 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac
Number of subjects: 0
Study 2525984 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam 20 mg once a day
Number of subjects: 0
Study 2525984 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 50 mg three times a day
Number of subjects: 0
Study 2525984 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg twice a day
Number of subjects: 0
Study 31514546 — intervention group
Group type: EXPERIMENTAL
Intervention: Tratinterol hydrochloride
Number of subjects: 732
Study 31514546 — intervention group
Group type: COMPARATOR
Intervention: Procaterol hydrochloride (active control)
Number of subjects: 732
Study 31190151 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue-engineered substitute for autologous oral mucosa
Number of subjects: 0
Study 31190151 — intervention group
Group type: COMPARATOR
Intervention: Urethrotomy
Number of subjects: 0
Study 31190151 — intervention group
Group type: COMPARATOR
Intervention: Injection of stem cells
Number of subjects: 0
Study 31190151 — intervention group
Group type: COMPARATOR
Intervention: Alternative tissue-engineered substitute
Number of subjects: 0
Study 28679430 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention, details not specified
Number of subjects: 0
Study 28679430 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 25803571 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly fractionated IPL
Number of subjects: 30
Study 25803571 — intervention group
Group type: COMPARATOR
Intervention: Biweekly conventional IPL
Number of subjects: 30
Study 23703134 — intervention group
Group type: EXPERIMENTAL
Intervention: Solvent-exposed subjects
Number of subjects: 48
Study 23703134 — intervention group
Group type: COMPARATOR
Intervention: Non-exposed subjects
Number of subjects: 48
Study 20962664 — intervention group
Group type: EXPERIMENTAL
Intervention: CAT stent
Number of subjects: 34
Study 20962664 — intervention group
Group type: COMPARATOR
Intervention: DES
Number of subjects: 34
Study 20962664 — intervention group
Group type: COMPARATOR
Intervention: BMS
Number of subjects: 34
Study 19439758 — intervention group
Group type: EXPERIMENTAL
Intervention: Local corticosteroid injection (25 mg prednisolone)
Number of subjects: 229
Study 19439758 — intervention group
Group type: EXPERIMENTAL
Intervention: Home training
Number of subjects: 229
Study 19439758 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial shock wave therapy
Number of subjects: 229
Study 17270320 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant administration of Tdap and influenza vaccines
Number of subjects: 720
Study 17270320 — intervention group
Group type: COMPARATOR
Intervention: Sequential administration of influenza vaccine followed by Tdap
Number of subjects: 720
Study 15541248 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium infusion
Number of subjects: 20
Study 15541248 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 20
Study 11853286 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral contraceptive (OC)
Number of subjects: 80
Study 11853286 — intervention group
Group type: COMPARATOR
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 80
Study 9635651 — intervention group
Group type: EXPERIMENTAL
Intervention: Tusk mask
Number of subjects: 23
Study 9635651 — intervention group
Group type: COMPARATOR
Intervention: Nonrebreather mask (NRM)
Number of subjects: 23